logo
← Back to all media

Historic drug pricing reform will not hinder biotech innovation

The elevated cost of prescription drugs has been the subject of numerous policy debates in America, where government support has historically been limited in comparison with single payer systems such as the UK’s. However, the potential impact of introducing legislative controls on prescription drug pricing has sparked debate within the healthcare sector, due to the risk of it disincentivising investment into the space and inhibiting innovation.

Published on 7th October 2022

Science background with molecule or atom Abstract structure for Science or medical background
Science background with molecule or atom Abstract structure for Science or medical background

Disclaimer

The information on this website may only be suitable for certain types of investors and is not intended to be used or relied upon by any other person.

An investment with IBT may contain significant risks and is intended only for sophisticated investors who meet certain eligibility criteria.

The material on this website is intended to be viewed only by persons resident in the UK.

The information on this website is not an offer to sell or a solicitation of an offer and does not constitute investment advice.

No representation, warranty or undertaking, express or implied, is given as to the accuracy or completeness of the information or opinions contained therein.

The information on this website may constitute financial promotion for the purposes of the Financial Services and Markets Act 2000 (“FSMA”).


I do not accept →